将公平理念融入异种移植的前景
肾移植面临器官短缺和分配不公两大挑战,基因编辑猪器官的异种移植有望解决供体问题。美国FDA和移植界正规划临床试验并融入常规诊疗。本文提出产业、监管、支付方、移植专业人员和患者团体可实施的公平框架,并呼吁立即行动。
要点
- 异种移植有望解决供体短缺,但需在试验和推广全程嵌入公平。
- 企业应组建患者倡导委员会,将终末期肾病患者关切置于前沿。
- 试验应与服务大量少数族裔患者且有社区互信的移植项目合作。
核心结论
- 异种移植有望解决供体短缺,但须在试验和常规诊疗各阶段促进公平。
- 企业、监管、支付方、移植专业人员和患者团体可实施本文提出的公平框架。
- 呼吁立即行动,让少数族裔社区成为异种移植的完全伙伴。
研究设计与样本
- 本文为综述/观点文章,未报告系统检索范围。
主要发现
- 基因编辑猪器官缺乏抗原并有其他修饰,应可降低移植入人体后的免疫排斥概率。
- 美国FDA和移植界领导者正规划异种移植临床试验并后续融入常规诊疗。
临床怎么用
- 开发异种移植技术的公司应组建患者倡导委员会,将终末期肾病患者关切置于前沿。
- 异种移植公司应与服务大量种族和族裔少数群体患者、并与这些社区有互信关系的移植项目合作开展试验。
- 上述公司和移植项目应即刻联系这些社区,告知异种移植信息并尝试回应其关切。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Two of the greatest challenges facing kidney transplantation are the lack of donated organs and inequities in who receives a transplant. Xenotransplantation holds promise as a treatment approach that could solve the supply problem. Major advances in gene-editing procedures have enabled several companies to raise genetically engineered pigs for organ donation. These porcine organs lack antigens and have other modifications that should reduce the probability of immunological rejection when transplanted into humans. The US Food and Drug Administration and transplantation leaders are starting to chart a path to test xenotransplants in clinical trials and later integrate them into routine clinical care. Here we provide a framework that industry, regulatory authorities, payers, transplantation professionals, and patient groups can implement to promote equity during every stage in this process. We also call for immediate action. Companies developing xenotransplant technology should assemble patient advocacy boards to bring the concerns of individuals with end-stage kidney disease to the forefront. For trials, xenotransplantation companies should partner with transplant programs with substantial patient populations of racial and ethnic minority groups and that have reciprocal relationships with those communities. Those companies and transplant programs should reach out now to those communities to inform them about xenotransplantation and try to address their concerns. These actions have the potential to make these communities full partners in the promise of xenotransplantation.
引用
- Reese PP, Powe NR, Lo B, et al. Engineering Equity Into the Promise of Xenotransplantation. Am J Kidney Dis. 2023. PMID: 37992981. doi:10.1053/j.ajkd.2023.09.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。